Document is current
Any future updates will be listed below
-
Authors
Cabel, Luc
An, Julia Ah-Reum
Kim, Hong-Kyu
Kim, Jisun
Smith, Christopher Gareth
Chevalier, Amber
Erazo, Tatiana
Moiso, Enrico
Ferraro, Emanuela
Safonov, Anton
Nelson, Konner
Szuhany, Kathleen
Drago, Joshua Z.
Norton, Larry
Xu, Amy
Khan, Atif J.
Li, Bob T.
Robson, Mark E.
Chandarlapaty, Sarat
Plitas, George
Razavi, Pedram
-
Funding
Funding for this research was provided by:
Neogenomics
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 25 November 2025
First Online: 29 January 2026
Competing interests
: CGS and AC are employees of NeoGenomicsMER COI declared uncompensated advisory for Foundation Medicine SC has received institutional funding from Daiichi-Sankyo and AstraZeneca, Share options in Totus Medicines, and consultation/Ad board/Honoraria from Daiichi-Sankyo, AstraZeneca, Lilly, Casdin Capital, and Pathos AI. S.C. is supported by grants from the BCRF and the NCI.PR reports Consulting/Ad Board/Advisory for Novartis, AstraZeneca, BioNTechLilly, Tempus, Prelude Therapeutics, NeoGenomics, Regor Pharmaceuticals, Natera, SAGA Diagnostics, Guardant Health, Myriad Genetics, Foresight Diagnostics and Institutional grant/funding support from Grail, Novartis, AstraZeneca, Biothernostics, Tempus, Sophia Genetics, Biovica, Guardant Health, Personalis, Myriad, Foresight Diagnostics, SAGA Diagnostics, Biodesix, Haystack, Roche. P.R. is supported by grants from Susan G. Komen, NCI, MBCure. JZD has received institutional grants/funding from Merck, AstraZeneca, Bolt Therapeutics, Jazz Pharmaceutics and Orum therapeutics, and has performed consulting/advisory work for AstraZeneca, Genagon, AmMax Bio, NuProbe, Revelio Therapeutics, MEDACorp, and BAIRD conferencesLC, JAA, HKK, JK, TE, EM, EF, AS, KN, KS, LN, AX, AJK, BTL, GP declare no financial or non-financial competing interests.
